Acitretin and pityriasis rubra pilaris – can we challenge deranged liver?

Pityriasis Rubra Pilaris (PRP) is a rare chronic inflammatory papulosquamous disease. It has variable clinical presentations with six subgroups1. We describe a patient presented with PRP type 1 with altered liver functions and dyslipidemia successfully treated with acitretin. Acitretin is considered first-line therapy2, although it has relative contraindications in patients with altered liver functions and may result in dyslipidemia and liver damage as a complication. Vigilant use of acitretin may be beneficial in a resource-poor setting to treat PRP.